EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization

Alexey Surov, Andreas Wienke, Jan Borggrefe, Timo Alexander Auer, Bernhard Gebauer, Aline Mähringer-Kunz, Felix Nensa, Johannes Haubold, Benedikt Michael Schaarschmidt, René Hosch, Jens Kleesiek, Thierno D Diallo und 9 weitere

Journal of Cancer Research and Clinical Oncology · 30.11.2024 · 150 (12)

DOI: 10.1007/s00432-024-06043-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 30.11.2024. Verfasst von Alexey Surov und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital Minden, Ruhr University Bochum, Bochum, Germany. a…. Hauptthemen laut MEDLINE: Chemoembolization, Therapeutic, Carcinoma, Hepatocellular, Liver Neoplasms, Muscle, Skeletal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mühlenkreiskliniken.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization (TACE).

Methods

We retrospectively enrolled 784 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. Intramuscular adipose tissue (IMAT) and skeletal muscle density (SMD) were estimated. Myosteatosis was defined as SMD < 28.0 HU for men and < 23.8 HU for women. Furthermore, albumin-SMD score (ADS) was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on survival, Cox regression model was used. Kaplan-Meier curves were used for survival analysis. Parameters of skeletal muscle quality were compared in univariate and multivariate regression analyses, adjusted for established risk factors.

Results

In the overall sample, survivors had higher SMD and ADS in comparison to non-survivors. Patients with low ADS had a lower OS than patients with high ADS (8.4 vs. 14.3 months, p < 0.001). In alcohol-induced HCC, none of the analyzed parameters of muscle quality influenced survival. In viral induced HCC, patients with low ADS had lower OS than patients with high ADS (8.8 vs. 15.7 months, p < 0.001). In patients with non-alcoholic steatohepatitis (NASH), none of the analyzed parameters of muscle quality influenced survival.

Conclusions

Low ADS is an independent predictor of worse OS in patients with viral-induced HCC undergoing treatment with TACE. In alcohol-induced and NASH-induced HCCs, parameters of muscle quality do not influence OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemoembolization, TherapeuticCarcinoma, HepatocellularLiver NeoplasmsMuscle, SkeletalHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPrognosisSerum AlbuminSurvival Rate

Stichwörter der Autor:innen

Hepatocellular cancerSkeletal musculatureSurvivalTransarterial chemoembolization

Substanzen

Serum Albumin

Autor:innen und Institutionen

  • Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital Minden, Ruhr University Bochum, Bochum, Germany. alexey.surov@gmx.de.
  • Department of Radiology, Charité - University Medicine Berlin, Berlin, Germany.
  • Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling University Hospital Minden, Ruhr University Bochum, Bochum, Germany.
  • Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther- University Halle-Wittenberg, Halle, Germany.
  • Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckst. 1, 55131, Mainz, Germany.
  • Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Förderung

  • Mühlenkreiskliniken

Zitieren

APA

Surov, A., Wienke, A., Borggrefe, J., Auer, T. A., Gebauer, B., Mähringer-Kunz, A., Nensa, F., Haubold, J., Schaarschmidt, B. M., Hosch, R., Kleesiek, J., Diallo, T. D., Roehlen, N., Bettinger, D., Eisenblätter, M., Steinle, V., Mayer, P., Zopfs, D., Pinto Dos Santos, D., …, & Kloeckner, R. (2024). Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 150(12). https://doi.org/10.1007/s00432-024-06043-3

Vancouver

Surov A, Wienke A, Borggrefe J, Auer TA, Gebauer B, Mähringer-Kunz A, et al. Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology. 2024;150(12). doi:10.1007/s00432-024-06043-3

BibTeX
@article{Surov2024,
  author = {Surov, Alexey and Wienke, Andreas and Borggrefe, Jan and Auer, Timo Alexander and Gebauer, Bernhard and Mähringer-Kunz, Aline and Nensa, Felix and Haubold, Johannes and Schaarschmidt, Benedikt Michael and Hosch, René and Kleesiek, Jens and Diallo, Thierno D and Roehlen, Natascha and Bettinger, Dominik and Eisenblätter, Michel and Steinle, Verena and Mayer, Philipp and Zopfs, David and Pinto Dos Santos, Daniel and Müller, Lukas and Kloeckner, Roman},
  title = {Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {12},
  doi = {10.1007/s00432-024-06043-3}
}
Kostenlos starten →